A method of production and composition of a humic substances-based topical gel that contains a high concentration of polymerized humic substances in the form of polyelectrolyte-enhanced biopolymers, allowing for targeted application of gel to skin. A method of production consists of selection of humic substances containing material, extraction of humic substances from the material, polymerization of humic substances, and further processing for product preservation. Such humic substances based material may be derived from brown coal, such as leonardite or lignite, or peat. An extraction technique for extraction of the humic substances is an alkali extraction method. Such a resulting composition may contain sodium silicate as a gelling agent for ease of application, and in some embodiments a preservative or combination of preservatives for shelf life. Such a humic substances-based topic gel is water soluble, allowing for in-home application and ability to discard through washing down a household drain.

The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.

Provided herein are materials and methods of reducing contamination in a biological substance or treating contamination in a subject by one or more toxins comprising contacting the biological substance with an effective amount of a sorbent capable of sorbing the toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and sorbing the toxin. Also provided are kits to reduce contamination by one or more toxins in a biological substance comprising a sorbent capable of sorbing a toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and a vessel to store said sorbent when not in use together with packaging for same.

Provided herein are materials and methods of reducing contamination in a biological substance or treating contamination in a subject by one or more toxins comprising contacting the biological substance with an effective amount of a sorbent capable of sorbing the toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and sorbing the toxin. Also provided are kits to reduce contamination by one or more toxins in a biological substance comprising a sorbent capable of sorbing a toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and a vessel to store said sorbent when not in use together with packaging for same.

The disclosed subject matter relates to the delivery of hydroxyl-containing compounds as microparticles for a variety of pharmaceutical, biomedical, cosmetics and personal care applications. This entails the manufacture and use of polymerized hydro-X compounds. Note is made of hydro-X compounds selected from the group consisting of curcuminoids, stilbenoids, resolvins, phenylethanoids, tocopherols, tocotrienols, flavanones, flavones, prenylflavonoids, isoflavones, isoflavanes, dihydrochalcones, isoflavenes, coumestans, lignans, flavonoligans, flavonols, mycoestrogens, xenoestrogens, phytoestrogens, sterols, corticosteroids, androgens, estrogens, stanols, steroids, secosteroids, tannins, statins, catechols, catechins, opioids, cannabinoids, pleuromutilins, luteolinidin, anthocyanidins, apigeninidin, glycosylated compounds, and macrolides.

Provided are body corrective cosmetic formulations and methods of use thereof.

Provided are body corrective cosmetic formulations and methods of use thereof.

Oral medicament comprising an osmotic laxative incorporated into a matrix based on plant fats. The present invention relates to an oral pharmaceutical composition comprising: between 30 and 55% by weight of said pharmaceutical composition of micronized anhydrous macrogol; and between 45 and 70% by weight of the pharmaceutical composition of a carrier consisting of an anhydrous hydrophobic lipid coating based on fatty compounds of plant origin, having a melting point of between 36 and 38° C., and to the use thereof as laxative. Said composition enables the reduction in the daily dosage of macrogol by preserving the osmotic pressure thereof as far as the colon, the site of therapeutic action of osmotic laxatives; said carrier protects the macrogol from a reduction, due to the moisture in the digestive tract, in the osmotic pressure.

Oral medicament comprising an osmotic laxative incorporated into a matrix based on plant fats. The present invention relates to an oral pharmaceutical composition comprising: between 30 and 55% by weight of said pharmaceutical composition of micronized anhydrous macrogol; and between 45 and 70% by weight of the pharmaceutical composition of a carrier consisting of an anhydrous hydrophobic lipid coating based on fatty compounds of plant origin, having a melting point of between 36 and 38° C., and to the use thereof as laxative. Said composition enables the reduction in the daily dosage of macrogol by preserving the osmotic pressure thereof as far as the colon, the site of therapeutic action of osmotic laxatives; said carrier protects the macrogol from a reduction, due to the moisture in the digestive tract, in the osmotic pressure.

Disclosed herein are compositions and methods for preventing or treating acute or chronic oral mucositis, esophagitis, enteritis, colitis, or gastrointestinal acute radiation syndrome (GI-ARS) caused by radiation exposure, using one or more enteron sorbent polymers administered gastrointestinally (e.g. orally, via feeding or gastric tube, via ostomy, or rectally).